|Bid||65.49 x 1300|
|Ask||65.69 x 1000|
|Day's Range||65.12 - 66.38|
|52 Week Range||63.07 - 81.44|
|Beta (5Y Monthly)||0.43|
|PE Ratio (TTM)||18.82|
|Earnings Date||Jul 27, 2023|
|Forward Dividend & Yield||2.28 (3.53%)|
|Ex-Dividend Date||Apr 06, 2023|
|1y Target Est||79.70|
Subscribe to Yahoo Finance Plus to view Fair Value for BMYLearn more
Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.
PRINCETON, N.J., June 04, 2023--Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with.....
Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors. Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation. David Jagielski (Bristol Myers Squibb): Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.
In this article, we will be taking a look at 10 stocks Jim Cramer and hedge funds have in common. To see more of these stocks, you can go directly to see 5 Stocks Jim Cramer and Hedge Funds Have In Common. “If You Use NVIDIA’s Chips, You Can Speak In The Vernacular Of ChatGPT” […]
Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.
Key Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable...
NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog.
Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session.
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and ICICI Bank Limited (IBN).
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.
Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.
In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […]
Shares of Walgreens Boots Alliance (NASDAQ: WBA), Bristol Myers Squibb (NYSE: BMY) and Dominion Energy (NYSE: D) all recently saw 52-week lows. Walgreens, like other pharmacy stocks, has seen earnings decline as foot traffic in stores has fallen. Pharmaceutical company Bristol Myers Squibb is facing increasing generic competition for its former top-selling oncology drug Relivimid, and has seen revenue decline.
NEW YORK, June 01, 2023--Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Its hefty yield isn't the only reason to consider buying this top pharma stock.
NEW YORK, May 31, 2023--Bristol Myers Squibb to Hold R&D Day on September 14
Pharmaceutical giant Bristol-Myers Squibb has been struggling for weeks and recently broke a key support zone. In this daily bar chart of BMY, below, I can see that prices made a high in early December and turned lower. Prices held the prior low around $66 in late August and again in March but that support zone gave way last week and prices sank lower.
PRINCETON, N.J., May 30, 2023--BMS to Present Late-Breaking Data for Breyanzi in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 ICML
PRINCETON, N.J., May 30, 2023--US FDA Accepts for Priority Review BMS's Application for Repotrectinib
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Bristol Myers Squibb Co (NYSE: BMY) announced the first disclosure of results from the primary analysis of the pivotal TRANSCEND CLL 004 Phase 1/2 study of Breyanzi (lisocabtagene maraleucel, liso-cel) in adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). At a median follow-up of 21.1 months, results show that Breyanzi delivered statistically significant complete response (CR) rates, the study's primary endpoint, in 18.4% of patients in the
PRINCETON, N.J., May 26, 2023--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable...